This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OVAS OvaScience (OVAS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About OvaScience Stock (NASDAQ:OVAS) Get OvaScience alerts:Sign Up Key Stats Today's Range$1.54▼$1.6150-Day Range$8.56▼$17.1052-Week Range$0.66▼$1.52Volume152,321 shsAverage Volume163,131 shsMarket Capitalization$55.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. Read More Receive OVAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OvaScience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OVAS Stock News HeadlinesAssisted Reproductive Technology Market to Surpass USD 40.67 Billion by 2031 | SkyQuest TechnologyAugust 9, 2024 | finance.yahoo.comGlobal Fertility Services Market Report 2024-2032, by Cause of Infertility, Procedure, Service, End-User and RegionMay 21, 2024 | uk.finance.yahoo.comDr. Ron Paul: “It’s time to prepare”The Pentagon has plans for military bases to survive a 90-day disaster. A former Defense Intelligence Agency staffer warns that the window to prepare, even with the basics, is closing. Dr. Ron Paul, 12-term former Congressman, says tech stocks are already in bear market territory while AI-driven cyberattacks grow by the day. He's teamed up with a leading financial expert to explain how he's preparing.November 4 at 1:00 AM | Stansberry Research (Ad)General Catalyst Group V LP's Net WorthFebruary 10, 2024 | benzinga.comGlobal In Vitro Fertilization Market Size To Worth USD 39.12 Billion By 2032 | CAGR of 5.5%December 7, 2023 | finance.yahoo.comOvascience (OVAS) Stock Drops After Pricing Public OfferingNovember 4, 2023 | thestreet.comGlobal Retail Automation Market Size 2023-2027 | Drivers, Product Types, Applications, Growth Analysis and ForecastJune 30, 2023 | finance.yahoo.comTMRW Life Sciences Names Louis Villalba Chief Executive OfficerJune 27, 2023 | markets.businessinsider.comSee More Headlines OVAS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of OvaScience own? Based on aggregate information from My MarketBeat watchlists, some other companies that OvaScience investors own include Gilead Sciences (GILD), OPKO Health (OPK), Bristol Myers Squibb (BMY), Netflix (NFLX), Celldex Therapeutics (CLDX), Esperion Therapeutics (ESPR) and GE Aerospace (GE). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OVAS CIK1544227 Webwww.ovascience.com Phone(734) 845-9000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.97 million Net Margins-10,128.37% Pretax MarginN/A Return on Equity-47.06% Return on Assets-42.39% Debt Debt-to-Equity RatioN/A Current Ratio12.62 Quick Ratio12.62 Sales & Book Value Annual Sales$290 thousand Price / Sales192.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.87Miscellaneous Outstanding Shares35,830,000Free FloatN/AMarket Cap$55.89 million OptionableNot Optionable Beta3.11 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:OVAS) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredDr. Ron Paul: “It’s time to prepare”The Pentagon has plans for military bases to survive a 90-day disaster. A former Defense Intelligence Agency s...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
